Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving circul
Promoting Recognition, Diagnosis and Treatment of Cold Agglutinin Disease
Claim This Podcastby Annenberg Center for Health Sciences
5 episodes
Updated Daily
Accepts GuestsHas Sponsors
Podcast Overview
Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving circul
Language
🇺🇲
Publishing Since
8/30/2021
1 verified contact email on file for Promoting Recognition, Diagnosis and Treatment of Cold Agglutinin Disease
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
August 30, 2021
Pathogenesis and Clinical Features of Cold Agglutinin Disease
<ul> <li>Cold Agglutinin Disease (CAD, a type of Autoimmune Hemolytic Anemia, AIHA) is a rare disease, challenging at presentation and can present acutely or with more chronic symptoms</li> <li><strong>CAD</strong> is a subtype of AIHA (accounting for ~20% of all AIHA) caused by IgM autoantibodies, which tend to react at cold temperatures; <strong>Cold Agglutinin Syndrome (CAS)</strong> is also an AIHA mediated by IgM, associated with systemic disease, most commonly infection or malignancy</li> <li>Hemolysis in CAD is complement-dependent with mainly extravascular hemolysis, typically in the liver</li> <li>CAD affects ~one person per million every year; middle-aged and elderly people, 40–80 years of age with average age of onset 60 years of age; more common in women than men</li> </ul>
August 30, 2021
Interactive Case Scenario
<ul> <li>Follow the case of a 62-year-old female who began to feel fatigue and shortness of breath in December 2010 through treatment to April 2017</li> </ul>
August 30, 2021
Emerging Treatments for Cold Agglutinin Disease
<ul> <li>Unmet medical need due to the high frequency of persistent anemia/hemolysis; immunochemotherapy is unsuccessful in at least 25% of cases because of treatment failure or toxicity; and small B-cell clone shows low proliferation activity and is difficult to target efficiently</li> <li>Need for rapid acting therapy, especially in specific clinical settings, such as acute and severe exacerbations due to infections, major surgery, trauma, cardiac surgery</li> <li>As of June 2021, there were six emerging treatments in trials, including Eculizumab, Bortezomib, Sutimlimab (BIVV009) in the CARDINAL and CADENZA trials, Pegcetacoplan (APL-2) and BIVV020 (both multiple and single IV doses)</li> <li>The CADENCE Registry, a global patient registry launched in 2019, is an important tool in treating CAD and will provide perspective longitudinal data to advance understanding of patient demographics, clinical presentation and characteristics, co-morbidities and disease burden, patterns and use of CA</li> </ul>
5 total episodes available
Deep-dive analytics for Promoting Recognition, Diagnosis and Treatment of Cold Agglutinin Disease
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Promoting Recognition, Diagnosis and Treatment of Cold Agglutinin Disease?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.